These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26368554)

  • 1. Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.
    Itakura J; Kurosaki M; Higuchi M; Takada H; Nakakuki N; Itakura Y; Tamaki N; Yasui Y; Suzuki S; Tsuchiya K; Nakanishi H; Takahashi Y; Maekawa S; Enomoto N; Izumi N
    PLoS One; 2015; 10(9):e0138060. PubMed ID: 26368554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.
    Nitta S; Asahina Y; Matsuda M; Yamada N; Sugiyama R; Masaki T; Suzuki R; Kato N; Watanabe M; Wakita T; Kato T
    Sci Rep; 2016 Oct; 6():34652. PubMed ID: 27703205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
    Yu JH; Lee JI; Lee KS; Kim JK
    Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.
    Uchida Y; Kouyama J; Naiki K; Sugawara K; Ando S; Nakao M; Motoya D; Inao M; Imai Y; Nakayama N; Mochida S
    J Gastroenterol; 2016 Mar; 51(3):260-70. PubMed ID: 26245700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing.
    Bergfors A; Leenheer D; Bergqvist A; Ameur A; Lennerstrand J
    Antiviral Res; 2016 Feb; 126():81-9. PubMed ID: 26707078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
    Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
    J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay.
    Kan T; Hashimoto S; Kawabe N; Murao M; Nakano T; Shimazaki H; Nakaoka K; Ohki M; Takagawa Y; Kurashita T; Takamura T; Yoshioka K
    J Gastroenterol; 2016 Jan; 51(1):63-70. PubMed ID: 25904097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b.
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Kawashima H; Ishikawa T; Tachi Y; Hattori M; Katano Y; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2018 Jan; 33(1):249-255. PubMed ID: 28440885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
    Ikeda H; Watanabe T; Okuse C; Matsumoto N; Ishii T; Yamada N; Shigefuku R; Hattori N; Matsunaga K; Nakano H; Hiraishi T; Kobayashi M; Yasuda K; Yamamoto H; Yasuda H; Kurosaki M; Izumi N; Yotsuyanagi H; Suzuki M; Itoh F
    J Med Virol; 2017 Jan; 89(1):99-105. PubMed ID: 27329864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
    Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
    Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.
    Parczewski M; Kordek J; Janczewska E; Pisula A; Łojewski W; Socha Ł; Wawrzynowicz-Syczewska M; Bociąga-Jasik M; Szymczak A; Cielniak I; Siwak E; Mularska E; Aksak-Wąs B; Urbańska A; Lübke N
    Clin Microbiol Infect; 2019 Apr; 25(4):513.e1-513.e6. PubMed ID: 29981869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
    Tornai I
    Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
    Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
    Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
    Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
    Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan.
    Tsai MC; Hung CH; Lu SN; Wang JH; Chen CH; Kee KM; Chang KC; Chao TL; Hu TH
    Biomed J; 2021 Dec; 44(6 Suppl 1):S126-S131. PubMed ID: 35123932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
    Morishita N; Sakamori R; Yamada T; Kai Y; Tahata Y; Urabe A; Yamada R; Kodama T; Hikita H; Doi Y; Tamura S; Hagiwara H; Imai Y; Iio S; Tatsumi T; Takehara T
    PLoS One; 2020; 15(6):e0234811. PubMed ID: 32544182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway.
    Kjellin M; Kileng H; Akaberi D; Palanisamy N; Duberg AS; Danielsson A; Kristiansen MG; Nöjd J; Aleman S; Gutteberg T; Goll R; Lannergård A; Lennerstrand J
    Scand J Gastroenterol; 2019 Aug; 54(8):1042-1050. PubMed ID: 31424972
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
    Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Zhang X; Setze C; Rodrigues L; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1106-13. PubMed ID: 26643326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.
    Peiffer KH; Sommer L; Susser S; Vermehren J; Herrmann E; Döring M; Dietz J; Perner D; Berkowski C; Zeuzem S; Sarrazin C
    Hepatology; 2016 Jan; 63(1):63-73. PubMed ID: 26406534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.